Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Drug companies have long considered KRas, a protein implicated in a large number of cancers, to be undruggable. But that’s starting to change as firms like Amgen, Mirati Therapeutics, and Revolution Medicines line up with new compounds that inhibit a specific mutant form of the protein called KRas G12C. In a nonexclusive partnership with Novartis, Mirati will test its KRas inhibitor in combination with Novartis’s experimental inhibitor of another protein, called SHP2, which is involved in the Ras pathway in cells. Separately, Revolution is developing its own inhibitors of KRas G12C and SHP2.
This article has been sent to the following recipient: